ArticleCellular and molecular life sciences : CMLS2026
C/EBPγ interacts with C/EBPα and activates the β-catenin pathway in idiopathic pulmonary fibrosis.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease characterized by an abnormal epithelial‒mesenchymal transition (EMT) and fibroblast activation, although the molecular mechanisms driving these processes remain unclear. Here, we report that the expression of CCAAT enhancer binding protein γ (C/EBPγ), a transcription factor, is significantly upregulated in lung tissues from patients with IPF and the lungs of mice with bleomycin-induced fibrosis. In A549 epithelial cells, C/EBPγ overexpression promoted the EMT, as indicated by decreased E-cadherin expression and increased N-cadherin and vimentin expression. In MRC-5 fibroblasts, C/EBPγ overexpression increased cell migration and upregulated the expression of fibrotic markers, including collagen I, fibronectin, and α-SMA. Mechanistically, C/EBPγ activated the β-catenin pathway by stabilizing β-catenin through the transcriptional repression of AXIN1, a key component of the degradation complex. This repression occurred via an interaction with C/EBPα, antagonizing its promotion of AXIN1 expression, as confirmed by ChIP‒qPCR, luciferase assays, coimmunoprecipitation, immunofluorescence staining, and rescue experiments. In vivo, adeno-associated virus-mediated C/EBPγ overexpression aggravated bleomycin-induced pulmonary fibrosis in mice, increasing collagen deposition, inflammation, and β-catenin expression, whereas C/EBPγ knockdown alleviated these changes. Collectively, these findings suggest that the downregulation of C/EBPγ expression attenuates fibrosis progression through the C/EBPα-AXIN1-β-catenin axis, underscoring its involvement in β-catenin pathway regulation and advancing the understanding of IPF pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.